Drug/NN
Target/NN
Identification/NN
and/CC
Elucidation/NN
of/IN
Natural/JJ
Inhibitors/NNS
for/IN
Bordetella/FW
petrii/NN
:/:
An/DT
In/IN
Silico/NN
Study/NN
./.
====================
Environmental/JJ
microbes/NNS
like/IN
Bordetella/FW
petrii/NN
has/VBZ
been/VBN
established/VBN
as/IN
a/DT
causative/JJ
agent/NN
for/IN
various/JJ
infectious/JJ
diseases/NNS
in/IN
human/JJ
./.
====================
Again/RB
,/,
development/NN
of/IN
drug/NN
resistance/NN
in/IN
B./FW
petrii/NN
challenged/VBN
to/TO
combat/VB
against/IN
the/DT
infection/NN
./.
====================
Identification/NN
of/IN
potential/JJ
drug/NN
target/NN
and/CC
proposing/VBG
a/DT
novel/JJ
lead/VBP
compound/NN
against/IN
the/DT
pathogen/NN
has/VBZ
a/DT
great/JJ
aid/VB
and/CC
value/NN
./.
====================
In/IN
this/DT
study/NN
,/,
bioinformatics/NNS
tools/NNS
and/CC
technology/NN
have/VBP
been/VBN
applied/VBN
to/TO
suggest/VB
a/DT
potential/JJ
drug/NN
target/NN
by/IN
screening/VBG
the/DT
proteome/JJ
information/NN
of/IN
B./FW
petrii/FW
DSM/NN
12804/CD
(/(
accession/NN
No/DT
./.
====================
PRJNA28135/NN
)/)
from/IN
genome/NN
database/NN
of/IN
National/JJ
Centre/NN
for/IN
Biotechnology/NN
information/NN
./.
====================
In/IN
this/DT
regards/VBZ
,/,
the/DT
inhibitory/JJ
effect/NN
of/IN
nine/CD
natural/JJ
compounds/NNS
like/IN
ajoene/JJ
(/(
Allium/NN
sativum/JJ
)/)
,/,
allicin/RB
(/(
A./NNP
sativum/JJ
)/)
,/,
cinnamaldehyde/RB
(/(
Cinnamomum/NNP
cassia/NN
)/)
,/,
curcumin/NN
(/(
Curcuma/NNP
longa/RB
)/)
,/,
gallotannin/NN
(/(
active/JJ
component/NN
of/IN
green/VBN
tea/NN
and/CC
red/JJ
wine/NN
)/)
,/,
isoorientin/NN
(/(
Anthopterus/JJ
wardii/LS
)/)
,/,
isovitexin/NN
(/(
A./NNP
wardii/NNP
)/)
,/,
neral/JJ
(/(
Melissa/NNP
officinalis/IN
)/)
,/,
and/CC
vitexin/FW
(/(
A./NNP
wardii/NNP
)/)
have/VBP
been/VBN
acknowledged/VBN
with/IN
anti-bacterial/JJ
properties/NNS
and/CC
hence/RB
tested/VBN
against/IN
identified/VBN
drug/NN
target/NN
of/IN
B./FW
petrii/IN
by/IN
implicating/VBG
computational/JJ
approach/DT
./.
====================
The/DT
in/IN
silico/JJ
studies/NNS
revealed/VBD
the/DT
hypothesis/NN
that/IN
lpxD/NN
could/MD
be/VB
a/DT
potential/JJ
drug/NN
target/NN
and/CC
with/IN
recommendation/NN
of/IN
a/DT
strong/JJ
inhibitory/JJ
effect/NN
of/IN
selected/VBN
natural/JJ
compounds/NNS
against/IN
infection/NN
caused/VBD
due/JJ
to/TO
B./FW
petrii/FW
,/,
would/MD
be/VB
further/RBR
validated/VBN
through/IN
in/IN
vitro/FW
experiments/NNS
./.
====================
Infectious/JJ
diseases/NNS
are/VBP
major/JJ
dreadful/JJ
threat/NN
to/TO
human/JJ
life/NN
,/,
spread/VBN
through/IN
many/JJ
causative/JJ
agents/NNS
like/IN
bacteria/NNS
,/,
fungus/JJ
,/,
virus/NN
,/,
etc/JJ
./.
====================
Therefore/RB
,/,
development/NN
of/IN
potential/JJ
drug/NN
is/VBZ
highly/RB
essential/JJ
to/TO
fight/CD
against/IN
infectious/JJ
diseases/NNS
./.
====================
Generally/RB
,/,
methods/NNS
of/IN
traditional/JJ
drug/NN
design/NN
are/VBP
tedious/JJ
,/,
time/NN
consuming/VBG
,/,
and/CC
cost/JJ
intensive/JJ
./.
====================
Hence/RB
,/,
several/JJ
multidisciplinary/JJ
approaches/NNS
have/VBP
gained/VBN
research/NN
attention/NN
to/TO
reduce/VB
the/DT
time/NN
and/CC
cost/JJ
during/IN
drug/NN
development/NN
process/NN
./.
====================
In/IN
silico/NN
drug/NN
design/NN
is/VBZ
one/CD
of/IN
such/JJ
approach/NN
,/,
provides/VBZ
remarkable/JJ
opportunity/NN
for/IN
identification/NN
of/IN
novel/JJ
lead/VBP
compounds/NNS
as/IN
comparison/NN
to/TO
other/JJ
conventional/JJ
methods/NNS
./.
====================
Drug/NN
target/NN
identification/NN
is/VBZ
an/DT
important/JJ
step/NN
involved/VBN
in/IN
computer/NN
aided/VBD
drug/NN
design/NN
process/NN
./.
====================
In/IN
this/DT
context/NN
,/,
the/DT
present/JJ
study/NN
is/VBZ
planned/VBN
to/TO
identify/VB
a/DT
potential/JJ
drug/NN
target/NN
against/IN
infectious/JJ
diseases/NNS
caused/VBD
by/IN
Bordetella/FW
petrii/NN
using/VBG
various/JJ
computational/JJ
tools/NNS
and/CC
techniques/NNS
./.
====================
B./FW
petrii/FW
is/VBZ
a/DT
gram-negative/JJ
coccobacilli/NN
of/IN
the/DT
phylum/NN
Proteobacteria/NN
,/,
has/VBZ
been/VBN
found/VBN
exclusively/RB
in/IN
close/JJ
association/NN
with/IN
humans/NNS
and/CC
various/JJ
warm-blooded/VBD
animals/NNS
due/JJ
to/TO
its/PRP$
independent/JJ
existence/NN
as/IN
an/DT
environmental/JJ
facultative/JJ
anaerobe/NN
[/(
1/CD
]/)
./.
====================
B./FW
petrii/FW
exhibits/VBZ
the/DT
host/NN
associated/VBN
properties/NNS
,/,
and/CC
its/PRP$
strains/NNS
have/VBP
been/VBN
detected/VBN
from/IN
environmental/JJ
samples/NNS
like/IN
microbial/JJ
consortia/NN
degrading/VBG
aromatic/JJ
compounds/NNS
,/,
marine/JJ
sponges/NNS
,/,
polluted/JJ
soil/RB
and/CC
a/DT
grass/JJ
root/NN
consortium/NN
[/(
23456/CD
]/)
./.
====================
The/DT
genome/NN
of/IN
B./FW
petrii/NN
contains/VBZ
5,287,950/CD
base/NN
pairs/NNS
,/,
and/CC
has/VBZ
been/VBN
observed/VBN
with/IN
greatest/JJS
numbers/NNS
of/IN
expressed/VBN
virulence/IN
factors/NNS
[/(
7/CD
]/)
./.
====================
Infectious/JJ
diseases/NNS
like/IN
mandibular/JJ
osteomyelitis/NN
[/(
8/CD
]/)
,/,
suppurative/JJ
mastoiditis/NN
[/(
9/CD
]/)
,/,
chronic/JJ
pulmonary/JJ
diseases/NNS
[/(
10/CD
]/)
,/,
respiratory/JJ
infection/NN
in/IN
case/NN
of/IN
bronchiectasis/NN
and/CC
cystic/JJ
fibrosis/NN
[/(
1112/CD
]/)
have/VBP
been/VBN
reported/VBN
due/IN
to/TO
B./FW
petrii/FW
infection/NN
./.
====================
Again/RB
,/,
exposure/NN
to/TO
soil/JJ
or/CC
water/NN
containing/VBG
B./FW
petrii/NN
may/MD
lead/VB
to/TO
local/JJ
colonization/NN
and/CC
eventually/RB
serious/JJ
nosocomial/JJ
infections/NNS
[/(
1314/CD
]/)
./.
====================
Some/DT
other/JJ
bacteria/NNS
like/IN
Escherichia/FW
coli/FW
[/(
15/CD
]/)
,/,
Pseudomonas/NN
aeruginosa/NN
[/(
16/CD
]/)
,/,
Chlamydophila/NN
pneumoniae/FW
[/(
17/CD
]/)
,/,
Staphylococcus/FW
aureus/FW
[/(
18/CD
]/)
,/,
and/CC
Haemophilus/NN
influenzae/FW
[/(
19/CD
]/)
have/VBP
also/RB
been/VBN
identified/VBN
as/IN
a/DT
cause/JJ
for/IN
such/JJ
types/NNS
of/IN
infections/NNS
./.
====================
Many/JJ
Food/JJ
and/CC
Drug/NN
Administration/NN
(/(
FDA/NN
)/)
approved/JJ
drugs/NNS
have/VBP
been/VBN
used/VBN
against/IN
these/DT
pathogens/NNS
,/,
but/CC
those/DT
drugs/NNS
have/VBP
less/RBR
effect/NN
on/IN
B./FW
petrii/FW
due/JJ
to/TO
development/NN
of/IN
substantial/JJ
resistance/NN
[/(
10/CD
]/)
,/,
generated/VBN
an/DT
opportunity/NN
to/TO
identify/VB
a/DT
potential/JJ
drug/NN
target/NN
as/IN
well/RB
as/IN
to/TO
discover/RB
a/DT
novel/JJ
lead/VBP
compound/NN
against/IN
B./FW
petrii/FW
using/VBG
computational/JJ
techniques/NNS
./.
====================
Again/RB
,/,
due/JJ
to/TO
adverse/JJ
effect/NN
of/IN
most/JJS
of/IN
the/DT
anti-infectious/JJ
drugs/NNS
of/IN
synthetic/JJ
origin/NN
,/,
natural/JJ
compounds/NNS
with/IN
anti-infectious/JJ
properties/NNS
have/VBP
been/VBN
tested/VBN
in/IN
both/DT
in/FW
vivo/FW
and/CC
in/IN
vitro/FW
to/TO
be/VB
an/DT
alternative/JJ
approach/NN
towards/IN
the/DT
treatment/NN
./.
====================
In/IN
this/DT
context/NN
,/,
some/DT
of/IN
the/DT
natural/JJ
compounds/NNS
such/JJ
as/IN
ajoene/RB
(/(
Allium/NN
sativum/JJ
)/)
,/,
allicin/RB
(/(
A./NNP
sativum/JJ
)/)
,/,
cinnamaldehyde/JJ
(/(
Cinnamomum/NNP
cassia/NN
)/)
,/,
curcumin/NN
(/(
Curcuma/NNP
longa/RB
)/)
,/,
gallotannin/NN
(/(
active/JJ
component/NN
of/IN
green/VBN
tea/NN
and/CC
red/JJ
wine/NN
)/)
,/,
isoorientin/NN
(/(
Anthopterus/NN
wardii/LS
)/)
,/,
isovitexin/NN
(/(
A./NNP
wardii/LS
)/)
,/,
neral/JJ
(/(
Melissa/NNP
officinalis/IN
)/)
,/,
and/CC
vitexin/FW
(/(
A./NNP
wardii/LS
)/)
have/VBP
been/VBN
acknowledged/VBN
with/IN
anti-bacterial/JJ
properties/NNS
[/(
202122232425/CD
]/)
./.
====================
Curcumin/NN
is/VBZ
a/DT
naturally/RB
occurring/VBG
polyphenolic/JJ
compound/NN
,/,
a/DT
common/JJ
component/NN
of/IN
Indian/JJ
spice/RB
turmeric/JJ
,/,
having/VBG
anti-tumor/JJ
,/,
anti-oxidant/JJ
,/,
and/CC
anti-inflammatory/JJ
properties/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
as/IN
an/DT
agent/NN
to/TO
reduce/VB
bacterial/JJ
colony/NN
formation/NN
and/CC
inhibit/VBP
lung/NN
cancer/NN
progression/NN
in/IN
high-risk/JJ
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
patients/NNS
[/(
20/CD
]/)
./.
====================
Similarly/RB
,/,
gallotannin/NN
is/VBZ
an/DT
active/JJ
component/NN
of/IN
green/VBN
tea/NN
and/CC
red/JJ
wine/NN
has/VBZ
been/VBN
observed/VBN
as/IN
a/DT
potent/JJ
inhibitor/NN
of/IN
calcium-activated/JJ
Cl–/NN
channel/NN
,/,
may/MD
be/VB
used/VBN
for/IN
the/DT
treatment/NN
of/IN
cystic/JJ
fibrosis/NN
[/(
21/CD
]/)
./.
====================
Again/RB
,/,
in/IN
vitro/FW
study/NN
of/IN
three/CD
flavone/JJ
C-glycosides/NNS
such/JJ
as/IN
isoorientin/NN
,/,
vitexin/NN
,/,
and/CC
isovitexin/NN
isolated/VBN
from/IN
A./NNP
wardii/LS
have/VBP
been/VBN
reported/VBN
as/IN
potent/JJ
inhibitors/NNS
for/IN
interleukin-8/NN
,/,
and/CC
matrix/NN
metalloproteinase-1/NN
,/,
an/DT
inflammatory/JJ
marker/NN
in/IN
case/NN
of/IN
COPD/NN
[/(
22/CD
]/)
./.
====================
Moreover/RB
,/,
most/JJS
of/IN
the/DT
bacterial/JJ
infection/NN
caused/VBD
due/JJ
to/TO
formation/NN
of/IN
bio/NN
film/NN
in/IN
the/DT
host/NN
./.
====================
In/IN
this/DT
regard/NN
,/,
an/DT
active/JJ
compound/NN
cinnamaldehyde/NN
of/IN
C./FW
cassia/NN
have/VBP
been/VBN
identified/VBN
as/IN
a/DT
strong/JJ
inhibitor/NN
against/IN
quorum/NN
sensing/VBG
(/(
QS/NNS
)/)
biofilm/NN
formation/NN
due/JJ
to/TO
E./FW
coli/FW
,/,
and/CC
Vibrio/NN
harveyi/VBP
[/(
23/CD
]/)
infection/NN
./.
====================
Similarly/RB
,/,
two/CD
extracts/NNS
of/IN
A./NNP
sativum/JJ
namely/RB
allicin/NN
and/CC
ajoene/NN
have/VBP
been/VBN
accounted/VBN
for/IN
inhibitory/JJ
effect/NN
against/IN
P./FW
aeruginosa/NN
and/CC
E./FW
coli/FW
[/(
24/CD
]/)
./.
====================
Likewise/RB
,/,
neral/JJ
is/VBZ
an/DT
active/JJ
component/NN
of/IN
M./NNP
officinalis/IN
,/,
has/VBZ
been/VBN
reported/VBN
as/IN
anti-bacterial/JJ
,/,
anti-fungal/JJ
,/,
and/CC
anti-oxidant/JJ
properties/NNS
against/IN
P./NNP
aeruginosa/NN
,/,
Klebsiella/NN
pneumoniae/FW
,/,
S./NNP
aureus/FW
,/,
and/CC
Citrobacter/NN
koseri/FW
infection/NN
[/(
25/CD
]/)
,/,
and/CC
may/MD
be/VB
applied/VBN
for/IN
several/JJ
infectious/JJ
diseases/NNS
including/VBG
nosocomial/JJ
infection/NN
./.
====================
As/IN
,/,
all/DT
of/IN
these/DT
nine/CD
natural/JJ
compounds/NNS
have/VBP
been/VBN
established/VBN
with/IN
anti-bacterial/JJ
properties/NNS
,/,
may/MD
be/VB
useful/JJ
for/IN
treatment/NN
of/IN
B./FW
petrii/FW
infection/NN
,/,
encouraged/VBD
authors/NNS
to/TO
elucidate/VB
their/PRP$
inhibitory/JJ
effect/NN
against/IN
the/DT
putative/JJ
drug/NN
target/NN
of/IN
B./FW
petrii/FW
through/IN
in/IN
silico/JJ
approach/NN
./.
====================
Subtractive/JJ
proteomics/NNS
====================
The/DT
complete/JJ
protein/NN
datasets/NNS
of/IN
B./FW
petrii/NN
(/(
whole/JJ
genome/NN
project/NN
accession/NN
No/DT
./.
====================
PRJNA28135/NN
)/)
were/VBD
retrieved/VBN
from/IN
Genome/NN
database/NN
of/IN
National/JJ
Centre/NN
for/IN
Biotechnology/NN
Information/NN
(/(
NCBI/NN
)/)
web/NN
server/RB
(/(
http/NN
:/:
//www.ncbi.nlm.nih/JJ
./.
====================
gov/genome//DT
)/)
./.
====================
The/DT
essentiality/NN
search/VBP
[/(
26/CD
]/)
was/VBD
carried/VBN
out/RP
through/IN
the/DT
Database/NN
of/IN
Essential/JJ
Gene/NN
(/(
DEG/NN
)/)
for/IN
screening/VBG
out/IN
the/DT
essential/JJ
proteins/NNS
responsible/JJ
for/IN
the/DT
survival/NN
of/IN
B./FW
petrii/FW
in/IN
the/DT
host/NN
./.
====================
The/DT
bit/NN
score/RB
parameter/NN
was/VBD
considered/VBN
as/IN
greater/JJR
or/CC
equal/JJ
to/TO
100/CD
for/IN
homology/NN
search/NN
using/VBG
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
(/(
BLAST/NN
)/)
while/IN
accessing/VBG
DEG/NN
(/(
http/NN
:/:
//tubic.tju.edu.cn/deg/blast.php/JJ
)/)
database/NN
,/,
to/TO
select/VB
bacterial/JJ
essential/JJ
proteins/NNS
./.
====================
The/DT
non-redundancy/NN
search/VBP
was/VBD
performed/VBN
through/IN
CD-HIT/NN
(/(
http/NN
:/:
//weizhong-lab.ucsd.edu/cdhit_suite/cgi-bin/index.cgi/NNP
)/)
web/NN
server/RB
to/TO
remove/VB
the/DT
redundant/JJ
proteins/NNS
among/IN
selected/VBN
essential/JJ
proteins/NNS
of/IN
B./FW
petrii/NN
./.
====================
Further/RB
,/,
by/IN
considering/VBG
the/DT
resulted/VBD
proteins/NNS
of/IN
B./FW
petrii/FW
,/,
the/DT
sequence/NN
similarity/NN
search/VBP
was/VBD
carried/VBN
out/RP
against/IN
human/JJ
[/(
272829/CD
]/)
followed/VBN
by/IN
human/JJ
gut/NN
flora/NN
microorganisms/NNS
[/(
3031/CD
]/)
using/VBG
BLASTP/NN
algorithm/NN
to/TO
eliminate/VB
proteins/NNS
homologous/JJ
with/IN
human/JJ
and/CC
human/JJ
gut/NN
flora/NN
microorganisms/NNS
respectively/RB
./.
====================
During/IN
similarity/NN
search/VBP
,/,
the/DT
threshold/NN
for/IN
expected/VBN
value/NN
(/(
e-value/JJ
)/)
was/VBD
fixed/JJ
as/IN
greater/JJR
or/CC
equal/JJ
to/TO
0.001/CD
./.
====================
Furthermore/RB
,/,
the/DT
protein/NN
sequences/NNS
which/WDT
are/VBP
putative/JJ
,/,
unknown/JJ
,/,
hypothetical/JJ
,/,
probable/JJ
,/,
conserved/VBN
hypothetical/JJ
and/CC
unnamed/JJ
protein/NN
were/VBD
removed/VBN
manually/RB
./.
====================
The/DT
study/NN
of/IN
sub/NN
cellular/JJ
localization/NN
was/VBD
performed/VBN
to/TO
identify/VB
the/DT
cytoplasm/NN
proteins/NNS
among/IN
the/DT
selected/VBN
proteins/NNS
[/(
32/CD
]/)
using/VBG
CELLO/NN
(/(
http/NN
:/:
//cello.life.nctu.edu.tw//JJ
)/)
./.
====================
Generally/RB
,/,
proteins/NNS
are/VBP
annotated/VBN
and/CC
ranked/VBD
as/IN
per/IN
their/PRP$
evidence/NN
level/NN
in/IN
UniProt/JJ
database/NN
which/WDT
is/VBZ
also/RB
a/DT
factor/NN
to/TO
be/VB
considered/VBN
while/IN
selecting/VBG
putative/JJ
drug/NN
targets/NNS
./.
====================
Afterwards/IN
,/,
the/DT
Virulence/NN
Factor/NN
Database/NN
(/(
VFDB/NN
)/)
was/VBD
explored/VBN
,/,
and/CC
the/DT
virulence/NN
proteins/NNS
were/VBD
screened/VBN
out/IN
(/(
http/NN
:/:
//www.mgc.ac.cn/VFs/blast/blast.html/JJ
)/)
among/IN
the/DT
selected/VBN
targets/NNS
of/IN
B./FW
petrii/FW
through/IN
VFDB/NN
BLASTP/NN
search/VBP
against/IN
VFDB/NN
core/NN
data/NNS
sets/NNS
with/IN
consideration/NN
of/IN
threshold/JJ
e-value/JJ
as/IN
greater/JJR
than/IN
0.0001/CD
[/(
31/CD
]/)
./.
====================
The/DT
above/JJ
methodology/NN
is/VBZ
described/VBN
through/IN
a/DT
flow/NN
diagram/NN
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Pathway/NN
analysis/NN
====================
The/DT
participation/NN
of/IN
virulent/JJ
proteins/NNS
in/IN
any/DT
unique/JJ
pathways/NNS
of/IN
pathogen/NN
could/MD
be/VB
ensured/VBN
and/CC
analyzed/VBD
through/IN
the/DT
exploration/NN
of/IN
databases/NNS
,/,
is/VBZ
a/DT
common/JJ
procedure/NN
to/TO
be/VB
followed/VBN
while/IN
predicting/VBG
putative/JJ
drug/NN
targets/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
pathway/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
Kyoto/JJ
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
database/NN
(/(
http/NN
:/:
//www.genome.jp/kegg//JJ
)/)
./.
====================
Here/RB
,/,
the/DT
exploration/NN
of/IN
KEGG/NN
database/NN
for/IN
pathway/NN
study/NN
was/VBD
conducted/VBN
twice/RB
./.
====================
In/IN
the/DT
first/JJ
case/NN
,/,
the/DT
search/NN
was/VBD
carried/VBN
out/RP
for/IN
all/DT
obtained/VBN
virulent/JJ
proteins/NNS
against/IN
existing/VBG
pathways/NNS
of/IN
B./FW
petrii/NN
using/VBG
KEGG/NN
BLAST/NN
algorithm/NN
./.
====================
Secondly/RB
,/,
unique/JJ
pathways/NNS
of/IN
B./FW
petrii/FW
(/(
pathways/NNS
present/JJ
in/IN
B./FW
petrii/FW
,/,
not/RB
in/IN
human/JJ
)/)
were/VBD
sort/RB
listed/VBN
from/IN
the/DT
KEGG/NN
database/NN
by/IN
comparing/VBG
all/DT
pathways/NNS
between/IN
B./FW
petrii/FW
and/CC
human/JJ
./.
====================
Further/RB
,/,
selection/NN
of/IN
common/JJ
unique/JJ
pathways/NNS
[/(
263233/CD
]/)
was/VBD
made/VBN
between/IN
the/DT
observed/VBN
pathways/NNS
of/IN
selected/VBN
targets/NNS
and/CC
obtained/VBN
unique/JJ
pathways/NNS
of/IN
B./FW
petrii/NN
./.
====================
Furthermore/RB
,/,
the/DT
selection/NN
pathways/NNS
which/WDT
are/VBP
essential/JJ
for/IN
the/DT
survival/NN
of/IN
the/DT
pathogen/NN
were/VBD
made/VBN
after/IN
detail/NN
inspection/NN
of/IN
obtained/VBN
pathways/NNS
./.
====================
Finally/RB
,/,
the/DT
key/JJ
proteins/NNS
regulating/VBG
those/DT
pathways/NNS
of/IN
B./FW
petrii/NN
were/VBD
considered/VBN
as/IN
putative/JJ
drug/NN
targets/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Protein-protein/NN
network/NN
study/NN
====================
The/DT
putative/JJ
drug/NN
targets/NNS
of/IN
B./FW
petrii/NN
obtained/VBN
after/IN
pathway/NN
analysis/NN
were/VBD
subjected/VBN
for/IN
protein-protein/JJ
network/NN
analysis/NN
using/VBG
STRING/NN
(/(
http/NN
:/:
//string-db.org//JJ
)/)
web/NN
server/RB
./.
====================
Here/RB
,/,
the/DT
interaction/NN
between/IN
the/DT
drugs/NNS
targets/NNS
were/VBD
quantified/VBN
on/IN
the/DT
basis/NN
[/(
34/CD
]/)
of/IN
confidence/NN
value/NN
(/(
0.007/CD
)/)
and/CC
the/DT
level/NN
of/IN
interaction/NN
(/(
maximum/NN
as/IN
50/CD
)/)
./.
====================
The/DT
drug/NN
targets/NNS
observed/VBN
as/IN
having/VBG
higher/JJR
numbers/NNS
of/IN
interaction/NN
with/IN
other/JJ
drug/NN
targets/NNS
among/IN
the/DT
chosen/NN
data/NNS
sets/NNS
were/VBD
considered/VBN
for/IN
further/JJ
analysis/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Similarity/NN
search/VBP
and/CC
domain/NN
prediction/NN
====================
Similarly/RB
search/VBP
was/VBD
carried/VBN
out/RP
for/IN
selected/VBN
proteins/NNS
using/VBG
BLASTP/NN
algorithm/NN
against/IN
Protein/NN
Data/NNS
Bank/NN
(/(
PDB/NN
)/)
database/NN
(/(
http/NN
:/:
//www.rcsb.org/pdb//JJ
)/)
./.
====================
The/DT
closest/JJS
homolog/NN
for/IN
each/DT
selected/VBN
target/NN
protein/NN
was/VBD
considered/VBN
as/IN
template/JJ
based/VBN
on/IN
lowest/JJS
e-value/JJ
and/CC
highest/JJS
percentage/NN
of/IN
similarity/NN
The/DT
conserved/VBN
domain/NN
region/NN
of/IN
potential/JJ
drug/NN
target/NN
was/VBD
predicted/VBN
using/VBG
conserved/VBN
domain/NN
database/NN
(/(
CDD/NN
)/)
of/IN
NCBI/NN
web/NN
server/RB
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi/NNP
)/)
with/IN
default/JJ
parameters/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Structure/NN
prediction/NN
and/CC
evaluation/NN
====================
Phyre2/NN
(/(
Protein/NN
Homology/Analogy/NN
Recognition/NN
Engine/NN
)/)
server/RB
was/VBD
used/VBN
for/IN
modelling/VBG
of/IN
three/CD
dimensional/JJ
structure/NN
of/IN
putative/JJ
drug/NN
target/NN
of/IN
B./FW
petrii/NN
./.
====================
The/DT
algorithm/NN
of/IN
Phyre2/NN
server/RB
predict/VBP
three/CD
dimensional/JJ
structure/NN
of/IN
a/DT
protein/NN
sequence/NN
using/VBG
the/DT
principles/NNS
and/CC
techniques/NNS
of/IN
homology/NN
and/or/CC
fold/JJ
recognition/NN
,/,
as/IN
structural/JJ
folding/VBG
pattern/NN
is/VBZ
more/RBR
conserved/VBN
in/IN
evolution/NN
than/IN
its/PRP$
amino/NN
acid/NN
sequence/NN
./.
====================
Hence/RB
,/,
a/DT
protein/NN
of/IN
interest/NN
(/(
drug/NN
target/NN
)/)
can/MD
be/VB
modelled/VBN
with/IN
reasonable/JJ
accuracy/NN
basing/VBG
on/IN
a/DT
distantly/RB
related/JJ
protein/NN
with/IN
known/VBN
(/(
template/NN
)/)
structure/NN
[/(
35/CD
]/)
./.
====================
The/DT
energetically/RB
stable/JJ
structure/NN
was/VBD
obtained/VBN
through/IN
structural/JJ
refinement/JJ
and/CC
energy/NN
minimization/NN
using/VBG
ModRefiner/JJ
algorithm/NN
[/(
36/CD
]/)
of/IN
Zhang/NNP
Lab/NN
web/NN
server/RB
(/(
http/NN
:/:
//zhanglab.ccmb.med.umich.edu/ModRefiner//JJ
)/)
./.
====================
The/DT
structural/JJ
superimposition/NN
of/IN
refined/VBN
model/NN
with/IN
template/NN
model/NN
was/VBD
performed/VBN
using/VBG
Discovery/NN
Studio/NN
3.5/CD
suite/JJ
./.
====================
The/DT
structural/JJ
quality/NN
and/CC
reliability/NN
of/IN
refined/VBN
model/NN
were/VBD
evaluated/VBN
using/VBG
RAMPAGE/NN
[/(
37/CD
]/)
,/,
ProSA-web/NN
[/(
38/CD
]/)
,/,
Protein/NN
Quality/NN
Predictor/NN
(/(
ProQ/NN
)/)
[/(
39/CD
]/)
,/,
and/CC
ERRAT/NN
[/(
40/CD
]/)
web/NN
tools/NNS
./.
====================
Preparation/NN
of/IN
natural/JJ
compounds/NNS
====================
The/DT
chemical/JJ
structures/NNS
of/IN
nine/CD
phytochemicals/NNS
(/(
ajoene/NN
,/,
allicin/NN
,/,
cinnamaldehyde/JJ
,/,
curcumin/NN
,/,
gallotannin/NN
,/,
isoorientin/NN
,/,
isovitexin/NN
,/,
neral/JJ
,/,
and/CC
vitexin/FW
)/)
were/VBD
downloaded/VBN
from/IN
PubChem/JJ
database/NN
of/IN
NCBI/NN
web/NN
server/RB
(/(
http/NN
:/:
//ncbi.nlm.nih.gov/pccompound/JJ
)/)
./.
====================
The/DT
correction/NN
of/IN
structural/JJ
geometry/NN
and/CC
energy/NN
minimization/NN
were/VBD
carried/VBN
out/RP
using/VBG
Discovery/NN
Studio/NN
3.5/CD
suites/VBZ
./.
====================
Molecular/JJ
docking/NN
====================
Molecular/JJ
docking/NN
between/IN
the/DT
predicted/VBN
model/NN
of/IN
potential/JJ
drug/NN
target/NN
with/IN
each/DT
of/IN
the/DT
nine/CD
natural/JJ
compounds/NNS
was/VBD
conducted/VBN
using/VBG
AutoDock-4.2/NN
algorithm/NN
(/(
http/NN
:/:
//autodock.scripps.edu//JJ
)/)
,/,
by/IN
considering/VBG
the/DT
protein/NN
structure/NN
as/IN
rigid/JJ
whereas/IN
ligands/NNS
were/VBD
kept/IN
as/IN
flexible/JJ
./.
====================
AutoDock/NN
algorithm/NN
requires/VBZ
pre/VBP
calculated/VBN
grid/JJ
maps/VBZ
,/,
one/CD
for/IN
each/DT
atom/IN
type/NN
present/JJ
in/IN
the/DT
flexible/JJ
molecules/NNS
being/VBG
docked/VBN
,/,
and/CC
it/PRP
stores/VBZ
the/DT
potential/JJ
energy/NN
arising/VBG
from/IN
the/DT
interaction/NN
with/IN
rigid/JJ
macro/NN
molecules/NNS
[/(
41/CD
]/)
./.
====================
Ligands/NNS
were/VBD
docked/VBN
around/IN
the/DT
identified/VBN
conserved/VBN
region/NN
within/IN
the/DT
functional/JJ
domain/NN
of/IN
the/DT
selected/VBN
drug/NN
target/NN
./.
====================
The/DT
favorable/JJ
poses/VBZ
were/VBD
selected/VBN
on/IN
the/DT
basis/NN
of/IN
lowest/JJS
binding/NN
energy/NN
calculated/VBN
by/IN
AutoDock/NN
which/WDT
indicates/VBZ
for/IN
most/JJS
favorable/JJ
binding/NN
conformation/NN
between/IN
receptor/NN
and/CC
ligands/NNS
./.
====================
Docking/VBG
procedure/NN
was/VBD
carried/VBN
out/RP
as/IN
per/FW
normal/JJ
methodology/NN
for/IN
protein-ligand/NN
docking/NN
[/(
4243/CD
]/)
./.
====================
The/DT
visualization/NN
and/CC
analysis/NN
of/IN
interaction/NN
between/IN
docked/VBD
complexes/NNS
were/VBD
made/VBN
using/VBG
Discovery/NN
Studio/NN
3.5/CD
suites/VBZ
./.
====================
Screening/VBG
of/IN
putative/JJ
drug/NN
targets/NNS
====================
Availability/NN
of/IN
whole/JJ
genome/NN
information/NN
of/IN
B./FW
petrii/NN
DSM/NN
12804/CD
(/(
accession/NN
No/DT
./.
====================
PRJNA28135/NN
)/)
in/IN
Genome/NN
database/NN
of/IN
NCBI/NN
web/NN
server/RB
encouraged/VBN
authors/NNS
to/TO
retrieve/VB
the/DT
entire/JJ
set/NN
of/IN
5,031/CD
protein/NN
sequences/NNS
in/IN
order/NN
to/TO
identify/VB
a/DT
potential/JJ
drug/NN
target/NN
against/IN
it/PRP
./.
====================
Primarily/RB
,/,
screening/NN
was/VBD
made/VBN
through/IN
identification/NN
of/IN
essential/JJ
genes/NNS
of/IN
B./FW
petrii/NN
,/,
considered/VBN
as/IN
primitive/JJ
strategy/NN
[/(
26/CD
]/)
for/IN
target/NN
identification/NN
./.
====================
Here/RB
,/,
out/RP
of/IN
total/JJ
5,031/CD
proteins/NNS
,/,
only/RB
1,841/CD
were/VBD
obtained/VBN
as/IN
essential/JJ
proteins/NNS
and/CC
hence/RB
suspected/VBD
as/IN
primary/JJ
targets/NNS
of/IN
B./FW
petrii/NN
./.
====================
To/TO
remove/VB
redundancy/NN
[/(
2930/CD
]/)
among/IN
the/DT
putative/JJ
drug/NN
targets/NNS
,/,
a/DT
non-redundancy/NN
search/VBP
was/VBD
carried/VBN
out/RP
which/WDT
resulted/VBD
1,802/CD
proteins/NNS
as/IN
non-redundant/JJ
./.
====================
Search/DT
for/IN
sequence/NN
homology/NN
with/IN
human/JJ
proteins/NNS
is/VBZ
an/DT
essential/JJ
step/NN
to/TO
be/VB
followed/VBN
for/IN
identification/NN
of/IN
proteins/NNS
present/JJ
only/RB
in/IN
pathogen/NN
but/CC
not/RB
in/IN
human/JJ
[/(
272829/CD
]/)
./.
====================
Again/RB
,/,
due/JJ
to/TO
symbiotic/JJ
relationship/NN
among/IN
human/JJ
and/CC
human/JJ
gut/NN
micro/NNS
biota/NN
,/,
homology/NN
search/VBP
between/IN
proteins/NNS
of/IN
pathogen/NN
and/CC
human/JJ
gut/NN
flora/NN
microorganisms/NNS
is/VBZ
also/RB
a/DT
crucial/JJ
step/NN
[/(
3031/CD
]/)
to/TO
be/VB
performed/VBN
to/TO
eliminate/VB
the/DT
target/NN
proteins/NNS
which/WDT
are/VBP
homologous/JJ
to/TO
human/JJ
gut/NN
flora/NN
microorganism/NN
./.
====================
The/DT
resulted/VBD
799/CD
numbers/NNS
of/IN
proteins/NNS
of/IN
B./FW
petrii/FW
were/VBD
not/RB
shown/VBN
any/DT
significant/JJ
similarity/NN
with/IN
human/JJ
proteome/JJ
as/IN
well/RB
as/IN
human/JJ
gut/NN
flora/NN
proteome/JJ
,/,
hence/RB
were/VBD
selected/VBN
for/IN
downstream/JJ
analysis/NN
./.
====================
Furthermore/RB
,/,
the/DT
reduction/NN
in/IN
protein/NN
dataset/NN
was/VBD
done/VBN
by/IN
selecting/VBG
proteins/NNS
reported/VBD
as/IN
active/JJ
and/CC
as/IN
well/RB
as/IN
functional/JJ
./.
====================
Out/DT
of/IN
799/CD
proteins/NNS
,/,
only/RB
509/CD
numbers/NNS
of/IN
functionally/RB
characterized/VBN
proteins/NNS
were/VBD
selected/VBN
using/VBG
the/DT
information/NN
available/JJ
at/IN
UniProt/JJ
database/NN
./.
====================
As/IN
suggested/VBD
by/IN
the/DT
literature/NN
,/,
only/RB
cytoplasm/NN
proteins/NNS
are/VBP
suitable/JJ
drug/NN
targets/NNS
whereas/IN
membrane/NN
bound/VBD
proteins/NNS
are/VBP
generally/RB
considered/VBN
for/IN
vaccine/NN
development/NN
[/(
32/CD
]/)
./.
====================
Among/IN
them/PRP
only/RB
cytoplasm/NN
proteins/NNS
(/(
334/CD
numbers/NNS
)/)
were/VBD
considered/VBN
for/IN
further/JJ
study/NN
./.
====================
Furthermore/RB
,/,
screening/NN
was/VBD
carried/VBN
out/RP
on/IN
the/DT
basis/NN
of/IN
evidence/NN
report/VBP
./.
====================
As/IN
of/IN
UniProt/JJ
database/NN
report/VBP
,/,
the/DT
evidence/NN
which/WDT
supports/VBZ
the/DT
existence/NN
of/IN
proteins/NNS
are/VBP
classified/VBN
as/IN
:/:
(/(
1/LS
)/)
experimental/JJ
evidence/NN
at/IN
protein/NN
level/NN
;/:
(/(
2/CD
)/)
experimental/JJ
evidence/NN
at/IN
transcript/NN
level/NN
;/:
(/(
3/CD
)/)
protein/NN
inferred/VBD
from/IN
homology/NN
;/:
(/(
4/CD
)/)
protein/NN
predicted/VBN
;/:
and/CC
(/(
5/CD
)/)
protein/NN
uncertain/JJ
./.
====================
Out/CC
of/IN
these/DT
evidences/NNS
,/,
evidence/NN
at/IN
protein/NN
level/NN
is/VBZ
the/DT
best/JJS
choice/NN
for/IN
protein/NN
existence/NN
,/,
as/IN
it/PRP
indicates/VBZ
the/DT
existence/NN
of/IN
the/DT
protein/NN
experimentally/RB
./.
====================
But/CC
in/IN
the/DT
current/JJ
investigation/NN
,/,
not/RB
a/DT
single/JJ
protein/NN
has/VBZ
been/VBN
observed/VBN
satisfying/JJ
this/DT
criterion/NN
./.
====================
Only/RB
135/CD
proteins/NNS
which/WDT
were/VBD
inferred/VBN
from/IN
homology/NN
subjected/VBN
to/TO
virtual/JJ
study/NN
./.
====================
Identification/NN
of/IN
pathogenic/JJ
proteins/NNS
having/VBG
virulence/NN
factor/NN
is/VBZ
also/RB
obligatory/JJ
[/(
31/CD
]/)
while/IN
screening/NN
a/DT
drug/NN
target/NN
against/IN
any/DT
pathogenic/JJ
microorganism/NN
./.
====================
Therefore/RB
,/,
homology/NN
search/NN
was/VBD
carried/VBN
out/RP
between/IN
135/CD
numbers/NNS
of/IN
proteins/NNS
and/CC
the/DT
core/NN
virulence/NN
proteins/NNS
of/IN
B./FW
petrii/NN
using/VBG
VFDB/NN
BLAST/NN
./.
====================
The/DT
result/NN
suggested/VBD
,/,
out/RB
of/IN
135/CD
selected/VBN
proteins/NNS
only/RB
26/CD
number/NN
of/IN
proteins/NNS
found/VBN
with/IN
virulence/NN
factor/NN
,/,
which/WDT
strongly/RB
supported/VBD
for/IN
further/JJ
study/NN
to/TO
predict/VB
potential/JJ
drug/NN
target/NN
against/IN
B./FW
petrii/FW
(/(
Figs/NNS
./.
====================
1/CD
and/CC
2/CD
)/)
./.
====================
Analysis/NN
of/IN
metabolic/JJ
pathways/NNS
====================
The/DT
pathway/NN
analysis/NN
was/VBD
conducted/VBN
to/TO
screen/VB
out/IN
the/DT
putative/JJ
drug/NN
targets/NNS
and/CC
their/PRP$
involvement/NN
in/IN
important/JJ
and/CC
unique/JJ
pathways/NNS
of/IN
the/DT
pathogen/NN
B./FW
petrii/FW
which/WDT
are/VBP
essential/JJ
for/IN
the/DT
survival/NN
of/IN
the/DT
pathogen/NN
./.
====================
The/DT
preliminary/JJ
search/NN
in/IN
KEGG/NN
database/NN
suggested/VBD
for/IN
involvement/NN
of/IN
22/CD
proteins/NNS
in/IN
different/JJ
important/JJ
pathways/NNS
of/IN
B./FW
petrii/FW
,/,
and/CC
therefore/RB
the/DT
dataset/NN
of/IN
putative/JJ
drug/NN
target/NN
reduced/VBD
from/IN
26/CD
to/TO
22/CD
./.
====================
Further/RB
,/,
exploration/NN
of/IN
all/DT
available/JJ
pathways/NNS
for/IN
both/DT
human/JJ
and/CC
pathogen/NN
was/VBD
conducted/VBN
and/CC
compared/VBD
,/,
resulted/VBD
38/CD
unique/JJ
pathways/NNS
present/JJ
in/IN
B./FW
petrii/FW
but/CC
absent/JJ
in/IN
human/JJ
./.
====================
Furthermore/RB
,/,
the/DT
comparison/NN
was/VBD
made/VBN
between/IN
the/DT
identified/VBN
important/JJ
pathways/NNS
of/IN
B./FW
petrii/FW
for/IN
22/CD
drug/NN
targets/NNS
and/CC
38/CD
unique/JJ
pathways/NNS
identified/VBN
in/IN
B./FW
petrii/FW
,/,
resulted/VBD
12/CD
putative/JJ
drug/NN
targets/NNS
(/(
Table/JJ
1/CD
)/)
contributing/VBG
towards/IN
the/DT
3/CD
common/JJ
and/CC
unique/JJ
pathways/NNS
of/IN
B./FW
petrii/FW
namely/RB
,/,
lipopolysaccharide/NN
biosynthesis/NN
,/,
two/CD
component/NN
system/NN
,/,
and/CC
bacterial/JJ
chemotaxis/NN
./.
====================
As/IN
per/IN
literature/NN
suggest/VBP
,/,
lipopolysaccharide/NN
biosynthesis/NN
is/VBZ
an/DT
essential/JJ
pathway/NN
[/(
44/CD
]/)
for/IN
the/DT
survival/NN
of/IN
B./FW
petrii/FW
,/,
a/DT
major/JJ
component/NN
of/IN
the/DT
outer/JJ
membrane/NN
of/IN
gram/NN
negative/JJ
bacteria/NNS
and/CC
referred/VBN
as/IN
endotoxin/NN
./.
====================
It/PRP
is/VBZ
comprised/VBN
of/IN
a/DT
hydrophilic/JJ
polysaccharide/NN
and/CC
a/DT
hydrophobic/JJ
component/NN
referred/VBN
as/IN
lipid/NN
A/NN
which/WDT
is/VBZ
responsible/JJ
for/IN
major/JJ
bio/NN
reactivity/NN
of/IN
endotoxin/NN
[/(
44/CD
]/)
,/,
also/RB
serves/VBZ
as/IN
a/DT
physical/JJ
barrier/NN
providing/VBG
protection/NN
towards/IN
bacteria/NNS
from/IN
its/PRP$
surroundings/NNS
[/(
45/CD
]/)
./.
====================
Intense/JJ
inspection/NN
on/IN
lipopolysaccharide/NN
biosynthesis/NN
pathway/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
suggested/VBD
,/,
out/RB
of/IN
12/CD
selected/VBN
putative/JJ
drug/NN
targets/NNS
(/(
Table/JJ
1/CD
)/)
only/RB
eight/CD
numbers/NNS
(/(
lpxH/NN
,/,
kdsB/NN
,/,
lpxK/NN
,/,
lpxD/NN
,/,
lpxB/NN
,/,
kdsA/NN
,/,
lpxC/NN
,/,
and/CC
Bpet0453/NN
)/)
were/VBD
as/IN
key/JJ
regulatory/JJ
proteins/NNS
[/(
46/CD
]/)
./.
====================
Again/RB
,/,
involvement/NN
of/IN
two/CD
components/NNS
namely/RB
,/,
amino/NN
acid/NN
and/CC
sugar/VBP
metabolism/NN
and/CC
pentose/NN
phosphate/NN
pathway/NN
were/VBD
found/VBN
as/IN
regulating/VBG
the/DT
complete/JJ
pathway/NN
./.
====================
lpxC/NN
,/,
lpxD/NN
,/,
lpxH/NN
,/,
lpxB/NN
,/,
and/CC
lpxK/NN
proteins/NNS
are/VBP
involved/VBN
in/IN
amino/NN
acid/NN
and/CC
sugar/VBP
metabolism/NN
,/,
and/CC
among/IN
them/PRP
lpxH/NN
was/VBD
discarded/VBN
as/IN
the/DT
synthesis/NN
of/IN
lpxB/NN
could/MD
alternatively/RB
possible/JJ
by/IN
lpxD/NN
./.
====================
Further/RB
,/,
lpxB/NN
and/CC
lpxK/NN
were/VBD
also/RB
rejected/VBD
as/IN
potential/JJ
drug/NN
target/NN
as/IN
the/DT
regulation/NN
of/IN
kdtA/NN
and/CC
waaA/NN
through/IN
lpxB/NN
and/CC
lpxK/NN
were/VBD
otherwise/RB
possible/JJ
by/IN
the/DT
proteins/NNS
involved/VBN
in/IN
pentose/NN
phosphate/NN
pathway/NN
./.
====================
Furthermore/RB
,/,
Bpet0453/NN
(/(
5.3.1.13/CD
)/)
,/,
kdsA/NN
(/(
2.5.1.55/CD
)/)
,/,
and/CC
kdsB/NN
(/(
2.7.7.38/CD
)/)
proteins/NNS
were/VBD
found/VBN
as/IN
key/JJ
proteins/NNS
of/IN
pentose/NN
phosphate/NN
metabolism/NN
components/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
,/,
and/CC
regulating/VBG
synthesis/NN
of/IN
kdtA/NN
and/CC
waaA/NN
,/,
but/CC
the/DT
synthesis/NN
of/IN
same/JJ
proteins/NNS
was/VBD
also/RB
control/VBP
by/IN
proteins/NNS
involved/VBN
in/IN
amino/NN
acid/NN
and/CC
sugar/VBP
metabolism/NN
to/TO
carried/VBN
out/RP
the/DT
whole/JJ
lipopolysaccharide/NN
biosynthesis/NN
./.
====================
So/RB
the/DT
key/JJ
proteins/NNS
kdsA/NN
,/,
kdsB/NN
,/,
and/CC
Bpet0453/NN
of/IN
pentose/NN
phosphate/NN
pathway/NN
were/VBD
discarded/VBN
./.
====================
Finally/RB
,/,
two/CD
proteins/NNS
namely/RB
lpxD/NN
and/CC
lpxC/NN
were/VBD
selected/VBN
on/IN
the/DT
basis/NN
of/IN
their/PRP$
highly/RB
involvement/NN
in/IN
the/DT
regulation/NN
of/IN
lipopolysaccharide/NN
biosynthesis/NN
pathway/NN
than/IN
any/DT
other/JJ
proteins/NNS
(/(
Figs/NNS
./.
====================
2B/NN
and/CC
3/CD
)/)
./.
====================
Protein/NN
network/NN
analysis/NN
====================
Protein/NN
network/NN
analysis/NN
is/VBZ
generally/RB
used/VBN
for/IN
selection/NN
of/IN
drug/NN
targets/NNS
having/VBG
interaction/NN
with/IN
maximum/JJ
numbers/NNS
of/IN
other/JJ
drug/NN
targets/NNS
,/,
an/DT
efficient/JJ
technique/NN
to/TO
discover/RB
a/DT
potent/JJ
drug/NN
target/NN
against/IN
pathogens/NNS
[/(
34/CD
]/)
./.
====================
Here/RB
,/,
the/DT
biological/JJ
interaction/NN
was/VBD
studied/VBN
for/IN
2/CD
obtained/VBN
drug/NN
targets/NNS
of/IN
B./FW
petrii/FW
,/,
and/CC
the/DT
assessment/JJ
supported/VBD
for/IN
both/DT
lpxD/JJ
(/(
with/IN
lpxC/NN
,/,
lpxB/NN
,/,
kdsA/NN
,/,
kdsB/NN
,/,
lpxH/NN
,/,
lpxK/NN
,/,
and/CC
bpet0453/IN
)/)
and/CC
lpxC/NN
(/(
with/IN
lpxD/NN
,/,
lpxB/NN
,/,
kdsA/NN
,/,
kdsB/NN
,/,
lpxK/NN
,/,
and/CC
bpet0453/IN
)/)
proteins/NNS
showing/VBG
interaction/NN
with/IN
other/JJ
drug/NN
targets/NNS
among/IN
the/DT
chosen/NN
data/NNS
set/VBP
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Therefore/RB
,/,
lpxD/NN
and/CC
lpxC/NN
proteins/NNS
were/VBD
strongly/RB
recommended/VBN
to/TO
be/VB
potential/JJ
drug/NN
targets/NNS
against/IN
the/DT
pathogen/NN
B./FW
petrii/NN
./.
====================
Identification/NN
of/IN
potent/JJ
drug/NN
target/NN
and/CC
domain/NN
prediction/NN
====================
Further/RB
,/,
template/NN
structure/NN
identification/NN
for/IN
lpxD/NN
and/CC
lpxC/NN
proteins/NNS
were/VBD
undergone/VBN
through/IN
similarity/NN
search/VBP
against/IN
PDB/NN
./.
====================
The/DT
template/JJ
protein/NN
structure/NN
(/(
PDB/NN
ID/NN
:/:
3PMO/CD
)/)
from/IN
P./NNP
aeruginosa/RB
was/VBD
selected/VBN
for/IN
the/DT
drug/NN
target/NN
lpxD/NN
of/IN
B./FW
petrii/FW
with/IN
91/CD
%/NN
query/RB
coverage/JJ
and/CC
49/CD
%/NN
of/IN
identity/NN
where/WRB
as/IN
template/JJ
structure/NN
(/(
PDB/NN
ID/NN
:/:
4FW3/CD
)/)
from/IN
P./NNP
aeruginosa/RB
for/IN
lpxC/NN
protein/NN
of/IN
B./FW
petrii/FW
with/IN
88/CD
%/NN
query/RB
coverage/JJ
and/CC
56/CD
%/NN
of/IN
identity/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
Though/IN
,/,
it/PRP
has/VBZ
been/VBN
already/RB
established/VBN
that/IN
lpxC/NN
catalyzes/VBZ
initially/RB
during/IN
the/DT
biosynthesis/NN
of/IN
the/DT
lipid/NN
A/NN
component/NN
of/IN
lipopolysaccharide/NN
and/CC
may/MD
be/VB
a/DT
potent/JJ
drug/NN
target/NN
to/TO
block/VB
the/DT
lipopolysaccharide/NN
pathway/NN
of/IN
pathogens/NNS
[/(
47/CD
]/)
,/,
the/DT
current/JJ
investigation/NN
suggested/VBD
,/,
the/DT
status/NN
of/IN
lpxC/NN
protein/NN
B./FW
petrii/FW
as/IN
un/JJ
reviewed/VBD
(/(
Table/JJ
3/CD
)/)
and/CC
have/VBP
shown/VBN
less/RBR
number/NN
of/IN
interaction/NN
with/IN
other/JJ
drug/NN
targets/NNS
in/IN
comparison/NN
to/TO
lpxD/JJ
(/(
Table/JJ
2/CD
)/)
./.
====================
Again/RB
,/,
as/IN
per/IN
literature/NN
report/VBP
,/,
lpxD/NN
has/VBZ
a/DT
key/JJ
role/NN
in/IN
biosynthesis/NN
of/IN
the/DT
lipid/NN
A/NN
component/NN
of/IN
lipopolysaccharide/NN
,/,
and/CC
its/PRP$
inhibitors/NNS
are/VBP
also/RB
potentially/RB
attractive/JJ
as/IN
antibacterial/JJ
agents/NNS
,/,
as/IN
there/EX
is/VBZ
no/DT
close/JJ
similarity/NN
found/VBN
with/IN
human/JJ
proteins/NNS
[/(
48/CD
]/)
./.
====================
Also/RB
,/,
lpxD/NN
has/VBZ
a/DT
vital/JJ
role/NN
in/IN
bio/NN
film/NN
formation/NN
which/WDT
is/VBZ
causing/VBG
nosocomial/JJ
infection/NN
[/(
16/CD
]/)
and/CC
the/DT
status/NN
obtained/VBN
from/IN
UniProt/JJ
web/NN
server/RB
as/IN
reviewed/VBN
(/(
Table/JJ
3/CD
)/)
./.
====================
This/DT
seems/VBZ
lpxD/NN
could/MD
be/VB
a/DT
potential/JJ
drug/NN
target/NN
against/IN
B./FW
petrii/NN
infection/NN
./.
====================
Therefore/RB
,/,
lpxD/NN
was/VBD
proposed/VBN
as/IN
a/DT
potent/JJ
drug/NN
target/NN
subjected/VBD
for/IN
further/JJ
in/IN
silico/NN
study/NN
./.
====================
Through/IN
BLAST/NN
search/VBP
and/CC
inspection/NN
in/IN
CDD/NN
database/NN
,/,
the/DT
conserved/VBN
amino/NN
acid/NN
resides/VBZ
within/IN
the/DT
left-handed/JJ
parallel/NN
beta/NN
helix/NN
(/(
LbH/JJ
)/)
domain/NN
of/IN
lpxD/NN
were/VBD
identified/VBN
(/(
Fig/NN
./.
====================
5A/DT
)/)
,/,
containing/VBG
three/CD
imperfect/JJ
tandem/JJ
repeats/NNS
of/IN
a/DT
hexapeptide/NN
repeat/NN
motif/NN
(/(
X-/JJ
[/(
STAV/NN
]/)
-X-/JJ
[/(
LIV/NN
]/)
-/:
[/(
GAED/JJ
]/)
-X/NN
)/)
./.
====================
Structure/NN
prediction/NN
and/CC
refinement/JJ
of/IN
proposed/JJ
drug/NN
target/NN
====================
Due/IN
to/TO
absence/NN
of/IN
experimental/JJ
structure/NN
the/DT
tertiary/JJ
model/NN
of/IN
lpxD/NN
(/(
UniProt/JJ
ID/NN
:/:
A9INS9/CD
)/)
protein/NN
was/VBD
predicted/VBN
by/IN
the/DT
single/JJ
highest/JJS
scoring/VBG
template/NN
i.e./FW
,/,
lpxD/NN
protein/NN
of/IN
P./FW
aeruginosa/NN
(/(
PDB/NN
ID/NN
:/:
3PMO/CD
,/,
chain/NN
A/DT
)/)
using/VBG
phyre2/NN
[/(
35/CD
]/)
web/NN
server/RB
with/IN
100/CD
%/NN
confidence/NN
./.
====================
Protein/NN
attains/NNS
the/DT
lowest/JJ
free/JJ
energy/NN
during/IN
the/DT
native/JJ
state/NN
;/:
therefore/RB
the/DT
stability/NN
of/IN
the/DT
predicted/VBN
model/NN
was/VBD
improved/VBN
through/IN
energy/NN
minimization/NN
[/(
36/CD
]/)
procedure/NN
,/,
supported/VBD
by/IN
the/DT
Root/NN
Mean/JJ
Square/JJ
Deviation/NN
score/RB
0.612/CD
obtained/VBN
through/IN
the/DT
structural/JJ
superimposition/NN
of/IN
lpxD/NN
models/NNS
both/CC
before/IN
and/CC
after/IN
energy/NN
minimization/NN
(/(
Fig/NN
./.
====================
5B/NN
)/)
./.
====================
The/DT
refined/VBN
lpxD/NN
protein/NN
model/NN
is/VBZ
publically/RB
available/JJ
in/IN
Protein/NN
Model/NN
Database/NN
with/IN
PMDB/NN
ID/NN
(/(
PM0080538/NN
)/)
./.
====================
Model/NN
evaluation/NN
of/IN
proposed/JJ
drug/NN
target/NN
====================
The/DT
correctness/NN
and/CC
quality/NN
of/IN
predicted/VBN
lpxD/NN
protein/NN
model/NN
of/IN
B./FW
petrii/FW
was/VBD
verified/VBN
through/IN
RAMPAGE/NN
[/(
37/CD
]/)
,/,
ProSA-web/NN
[/(
38/CD
]/)
,/,
ProQ/NN
[/(
39/CD
]/)
,/,
and/CC
ERRAT/NN
[/(
40/CD
]/)
online/RB
server/RB
./.
====================
The/DT
RAMPAGE/NN
analysis/NN
revealed/VBD
99.5/CD
%/NN
residues/NNS
were/VBD
folded/VBN
properly/RB
suggesting/VBG
good/JJ
backbone/NN
folding/VBG
pattern/NN
(/(
Fig/NN
./.
====================
5C/NN
)/)
./.
====================
Further/RB
,/,
Z-score/RB
for/IN
lpxD/NN
model/NN
calculated/VBN
by/IN
ProSA-web/NN
to/TO
be/VB
–6.84/CD
(/(
Fig/NN
./.
====================
5D/CD
)/)
which/WDT
is/VBZ
well/RB
within/IN
the/DT
range/NN
of/IN
native/JJ
conformation/NN
of/IN
experimental/JJ
structures/NNS
./.
====================
Furthermore/RB
,/,
ProQ/NN
computed/VBN
a/DT
Levitt-Gerstein/JJ
(/(
LG/NN
)/)
score/VBP
of/IN
2.785/CD
and/CC
Max/NN
sub/NN
score/RB
to/TO
be/VB
0.225/CD
for/IN
the/DT
predicted/VBN
model/NN
./.
====================
A/DT
ProQ/NN
LG/NN
score/RB
>/JJR
2.5/CD
is/VBZ
necessary/JJ
for/IN
suggesting/VBG
a/DT
model/NN
is/VBZ
of/IN
good/JJ
quality/NN
[/(
39/CD
]/)
,/,
implying/VBG
high/JJ
accuracy/NN
level/NN
of/IN
predicted/VBN
structure/NN
./.
====================
Also/RB
,/,
the/DT
overall/JJ
quality/NN
factor/NN
for/IN
lpxD/NN
model/NN
of/IN
B./FW
petrii/NN
was/VBD
predicted/VBN
as/IN
73.23/CD
%/NN
(/(
Fig/NN
./.
====================
5E/CD
)/)
by/IN
ERRAT/NN
web/NN
server/NN
./.
====================
All/DT
of/IN
these/DT
evaluations/NNS
recommended/VBN
the/DT
reliability/NN
of/IN
the/DT
predicted/VBN
lpxD/NN
model/NN
of/IN
B./FW
petrii/NN
./.
====================
Selection/NN
of/IN
natural/JJ
compounds/NNS
====================
As/IN
per/IN
literature/NN
survey/RB
,/,
nine/CD
natural/JJ
compounds/NNS
such/JJ
as/IN
ajoene/RB
(/(
A./NNP
sativum/JJ
)/)
,/,
allicin/RB
(/(
A./NNP
sativum/JJ
)/)
,/,
cinnamaldehyde/RB
(/(
C./NNP
cassia/NN
)/)
,/,
curcumin/NN
(/(
C./NNP
longa/RB
)/)
,/,
gallotannin/NN
(/(
active/JJ
component/NN
of/IN
green/VBN
tea/NN
and/CC
red/JJ
wine/NN
)/)
,/,
isoorientin/NN
(/(
A./NNP
wardii/NNP
)/)
,/,
isovitexin/NN
(/(
A./NNP
wardii/NNP
)/)
,/,
neral/JJ
(/(
M./NNP
officinalis/IN
)/)
,/,
and/CC
vitexin/FW
(/(
A./NNP
wardii/NNP
)/)
have/VBP
been/VBN
identified/VBN
with/IN
medicinal/JJ
properties/NNS
and/CC
reported/VBD
useful/JJ
against/IN
different/JJ
infectious/JJ
diseases/NNS
(/(
Table/JJ
4/CD
,/,
Fig/NN
./.
====================
6/CD
)/)
,/,
and/CC
hence/RB
downloaded/VBD
from/IN
PubChem/JJ
database/NN
of/IN
NCBI/NN
web/NN
server/RB
./.
====================
Molecular/JJ
docking/NN
analysis/NN
====================
The/DT
results/NNS
of/IN
molecular/JJ
docking/NN
were/VBD
intended/VBN
for/IN
energetically/RB
favorable/JJ
binding/VBG
poses/VBZ
for/IN
each/DT
nine/CD
natural/JJ
compounds/NNS
within/IN
the/DT
active/JJ
pocket/NN
(/(
LbH/JJ
domain/NN
)/)
of/IN
proposed/JJ
drug/NN
target/NN
of/IN
B./FW
petrii/FW
(/(
Fig/NN
./.
====================
5A/DT
)/)
as/IN
lowest/JJS
binding/NN
energy/NN
and/CC
inhibition/NN
constant/JJ
are/VBP
generally/RB
preferred/JJ
for/IN
favorable/JJ
binding/NN
mode/NN
while/IN
docking/NN
small/JJ
compounds/NNS
with/IN
target/NN
protein/NN
molecule/NN
[/(
4243/CD
]/)
./.
====================
Again/RB
,/,
among/IN
them/PRP
isoorientin/NN
(/(
–5.66/CD
kcal/mol/NN
)/)
,/,
curcumin/NN
(/(
–5.38/CD
kcal/mol/NN
)/)
,/,
isovitexin/NN
(/(
–5.22/CD
kcal/mol/NN
)/)
found/VBD
with/IN
lower/JJR
binding/VBG
energy/NN
and/CC
inhibition/NN
constants/NNS
i.e./FW
,/,
71.35/CD
µm/RB
,/,
114.67/CD
µm/RB
,/,
and/CC
149.85/CD
µm/RB
,/,
suggesting/VBG
as/IN
strong/JJ
inhibitors/NNS
of/IN
lpxD/NN
protein/NN
./.
====================
Further/RB
,/,
the/DT
binding/NN
stability/NN
was/VBD
proved/VBN
through/IN
existence/NN
of/IN
hydrogen/NN
bonding/VBG
pattern/NN
between/IN
the/DT
protein-ligand/NN
complexes/NNS
(/(
Table/JJ
5/CD
)/)
./.
====================
Presence/NN
of/IN
hydrophobic/JJ
amino/NN
acid/NN
residues/NNS
within/IN
the/DT
binding/NN
site/NN
highly/RB
contributes/VBZ
towards/IN
the/DT
stability/NN
during/IN
molecular/JJ
interaction/NN
between/IN
protein/NN
and/CC
small/JJ
compound/NN
./.
====================
Here/RB
,/,
the/DT
resulted/VBD
hydrophobic/JJ
interaction/NN
between/IN
the/DT
docked/VBN
complexes/NNS
also/RB
supported/VBD
for/IN
a/DT
strong/JJ
binding/NN
affinity/NN
of/IN
natural/JJ
compounds/NNS
towards/IN
the/DT
proposed/JJ
drug/NN
target/NN
(/(
lpxD/NN
)/)
of/IN
B./FW
petrii/FW
(/(
Table/JJ
6/CD
,/,
Fig/NN
./.
====================
7/CD
)/)
./.
====================
Also/RB
,/,
the/DT
presence/NN
of/IN
some/DT
positively/RB
and/CC
negatively/RB
charged/VBN
amino/NN
acid/NN
residues/NNS
of/IN
lpxD/NN
within/IN
4/CD
Å/NN
distance/NN
from/IN
the/DT
ligands/NNS
suggested/VBD
for/IN
electrostatic/JJ
force/IN
of/IN
interaction/NN
between/IN
docked/VBD
complexes/NNS
(/(
Table/JJ
6/CD
,/,
Fig/NN
./.
====================
7/CD
)/)
./.
====================
Again/RB
,/,
among/IN
nine/CD
active/JJ
natural/JJ
compounds/NNS
,/,
isoorientin/NN
(/(
–5.66/CD
kcal/mol/NN
)/)
was/VBD
observed/VBN
as/IN
the/DT
most/JJS
suitable/JJ
inhibitor/NN
with/IN
lowest/JJ
binding/VBG
energy/NN
and/CC
inhibition/NN
constant/JJ
(/(
71.35/CD
µm/RB
)/)
,/,
and/CC
formed/VBD
hydrogen/NN
bond/NN
with/IN
amino/NN
acid/NN
residues/NNS
like/IN
Ala/NN
186/CD
,/,
Glu/NNP
149/CD
,/,
and/CC
Gly/RB
227/CD
of/IN
lpxD/NN
(/(
Table/JJ
5/CD
,/,
Fig/NN
./.
====================
7F/CD
)/)
./.
====================
Strong/JJ
hydrophobic/JJ
interactions/NNS
were/VBD
seen/VBN
due/IN
to/TO
presence/NN
of/IN
Val/NN
165/CD
,/,
Ala/NN
186/CD
,/,
and/CC
Leu/NN
226/CD
within/IN
4/CD
Å/NN
distance/NN
from/IN
the/DT
ligand/NN
(/(
Table/JJ
6/CD
,/,
Fig/NN
./.
====================
7F/CD
)/)
./.
====================
All/DT
of/IN
these/DT
above/JJ
observation/NN
established/VBD
isoorientin/NN
to/TO
be/VB
a/DT
strong/JJ
inhibitor/NN
against/IN
lpxD/NN
of/IN
B./FW
petrii/NN
./.
====================
In/IN
conclusions/NNS
,/,
Identification/NN
of/IN
potential/JJ
drug/NN
target/NN
has/VBZ
a/DT
vital/JJ
role/NN
in/IN
designing/VBG
a/DT
novel/JJ
drug/NN
against/IN
any/DT
infectious/JJ
disease/NN
./.
====================
B./FW
petrii/NN
strains/NNS
have/VBP
been/VBN
reported/VBN
as/IN
causing/VBG
infections/NNS
in/IN
humans/NNS
and/CC
various/JJ
warm/NN
blooded/VBD
animals/NNS
./.
====================
In/IN
the/DT
present/JJ
investigation/NN
,/,
authors/NNS
attempted/VBD
to/TO
narrow/JJ
down/RB
the/DT
complete/JJ
data/NNS
set/VBP
of/IN
known/VBN
5,031/CD
protein/NN
sequences/NNS
of/IN
B./FW
petrii/FW
DSM/NN
12804/CD
(/(
accession/NN
No/DT
./.
====================
PRJNA28135/NN
)/)
in/IN
order/NN
to/TO
identify/VB
a/DT
potential/JJ
drug/NN
target/NN
computationally/RB
./.
====================
In/IN
silico/NN
study/NN
revealed/VBD
lpxD/NN
protein/NN
of/IN
B./FW
petrii/FW
as/IN
a/DT
potential/JJ
drug/NN
target/NN
,/,
is/VBZ
an/DT
essential/JJ
protein/NN
of/IN
the/DT
pathogen/NN
and/CC
involved/VBN
in/IN
the/DT
biosynthesis/NN
of/IN
the/DT
lipid/NN
A/NN
component/NN
of/IN
lipopolysaccharide/NN
./.
====================
Again/RB
,/,
the/DT
observations/NNS
made/VBD
through/IN
computational/JJ
study/NN
also/RB
strongly/RB
supported/VBD
lpxD/NN
to/TO
be/VB
a/DT
potential/JJ
drug/NN
target/NN
due/JJ
to/TO
the/DT
absence/NN
of/IN
lpxD/NN
protein/NN
in/IN
any/DT
human/JJ
essential/JJ
pathways/NNS
as/IN
well/RB
as/IN
without/IN
any/DT
significant/JJ
percentage/NN
of/IN
sequence/NN
homology/NN
with/IN
human/JJ
and/CC
human/JJ
gut/NN
flora/NN
micro/NNS
biota/NN
./.
====================
Again/RB
,/,
previous/JJ
literature/NN
reports/NNS
also/RB
established/VBN
the/DT
involvement/NN
of/IN
lpxD/NN
in/IN
nosocomial/JJ
infections/NNS
caused/VBN
due/JJ
to/TO
pathogens/NNS
and/CC
hence/RB
,/,
could/MD
be/VB
used/VBN
as/IN
a/DT
potential/JJ
drug/NN
target/NN
[/(
1516/CD
]/)
against/IN
B./FW
petrii/FW
./.
====================
Furthermore/RB
,/,
due/JJ
to/TO
adverse/JJ
effect/NN
of/IN
synthetic/JJ
drugs/NNS
,/,
the/DT
uses/VBZ
of/IN
active/JJ
natural/JJ
compounds/NNS
have/VBP
gained/VBN
an/DT
increasing/VBG
attention/NN
towards/IN
the/DT
treatment/NN
or/CC
prevention/NN
of/IN
infectious/JJ
diseases/NNS
./.
====================
Moreover/RB
,/,
some/DT
of/IN
the/DT
phytochemicals/NNS
like/IN
ajoene/DT
(/(
garlic/JJ
)/)
,/,
allicin/RB
(/(
ginger/RBR
)/)
,/,
cinnamaldehyde/RB
(/(
Chinese/JJ
cinnamon/JJ
)/)
,/,
curcumin/NN
(/(
turmeric/JJ
)/)
,/,
gallotannin/NN
(/(
green/RB
tea/RB
and/CC
red/JJ
wine/NN
)/)
,/,
isoorientin/RB
(/(
blueberry/RB
relative/JJ
found/VBN
in/IN
Central/JJ
and/CC
South/DT
America/NNP
)/)
,/,
isovitexin/IN
(/(
blueberry/RB
relative/JJ
found/VBN
in/IN
Central/JJ
and/CC
South/DT
America/NNP
)/)
,/,
neral/JJ
(/(
lemon/JJ
balm/RB
)/)
,/,
and/CC
vitexin/FW
(/(
blueberry/RB
relative/JJ
found/VBN
in/IN
Central/JJ
and/CC
South/DT
America/NNP
)/)
have/VBP
been/VBN
reported/VBN
as/IN
having/VBG
anti-oxidant/JJ
,/,
anti-inflammatory/JJ
,/,
and/CC
anti-bacterial/JJ
properties/NNS
,/,
might/MD
be/VB
used/VBN
against/IN
COPD/NN
,/,
cystic/JJ
fibrosis/NN
,/,
QS/NNP
biofilm/IN
formation/NN
,/,
nosocomial/JJ
infection/NN
,/,
and/CC
other/JJ
types/NNS
of/IN
bacterial/JJ
infection/NN
[/(
202122232425/CD
]/)
./.
====================
Therefore/RB
,/,
authors/NNS
excited/VBD
to/TO
apply/RB
molecular/JJ
docking/NN
approach/NN
to/TO
check/VB
the/DT
inhibitory/JJ
effects/NNS
of/IN
above/JJ
mentioned/JJ
nine/CD
natural/JJ
compounds/NNS
(/(
Table/JJ
4/CD
,/,
Fig/NN
./.
====================
6/CD
)/)
against/IN
the/DT
proposed/JJ
drug/NN
target/NN
(/(
lpxD/NN
)/)
of/IN
B./FW
petrii/NN
./.
====================
The/DT
docking/NN
study/NN
results/VBZ
also/RB
supported/VBD
for/IN
the/DT
confirmation/NN
of/IN
the/DT
mechanism/NN
of/IN
blocking/VBG
of/IN
lipid/NN
A/NN
biosynthesis/NN
in/IN
B./FW
petrii/FW
which/WDT
is/VBZ
essential/JJ
for/IN
the/DT
survival/NN
of/IN
the/DT
bacterium/NN
./.
====================
Again/RB
,/,
isoorientin/NN
was/VBD
noticed/VBN
with/IN
highest/JJS
inhibitory/JJ
effect/NN
among/IN
nine/CD
natural/JJ
compounds/NNS
supported/VBD
by/IN
lowest/JJS
binding/NN
energy/NN
and/CC
inhibition/NN
constant/JJ
(/(
Table/JJ
5/CD
)/)
./.
====================
Binding/NN
stability/NN
was/VBD
also/RB
confirmed/VBD
through/IN
observation/NN
of/IN
strong/JJ
hydrophobic/JJ
,/,
electrostatic/JJ
and/CC
hydrogen/NN
bonding/VBG
interactions/NNS
between/IN
protein-ligand/CC
complexes/NNS
(/(
Tables/NNS
5/CD
and/CC
6/CD
,/,
Fig/NN
./.
====================
7F/CD
)/)
./.
====================
Hence/RB
,/,
isoorientin/NN
could/MD
be/VB
suggested/VBN
as/IN
most/JJS
suitable/JJ
natural/JJ
compounds/NNS
against/IN
the/DT
proposed/JJ
drug/NN
target/NN
(/(
lpxD/NN
)/)
of/IN
B./FW
petrii/NN
./.
====================
The/DT
overall/JJ
hypothesis/NN
generated/VBN
through/IN
implementation/NN
of/IN
in/FW
silico/NN
approach/NN
would/MD
be/VB
a/DT
great/JJ
aid/VB
and/CC
value/NN
towards/IN
designing/VBG
a/DT
novel/JJ
drug/NN
against/IN
B./FW
petrii/FW
infection/NN
and/CC
which/WDT
would/MD
be/VB
further/RBR
validated/VBN
through/IN
in/IN
vitro/FW
experiments/NNS
./.
====================
The/DT
methodology/NN
of/IN
identification/NN
of/IN
potential/JJ
drug/NN
target/NN
of/IN
Bordetella/FW
petrii/NN
described/VBN
through/IN
flow/NN
diagram/NN
./.
====================
The/DT
methodology/NN
of/IN
subtractive/JJ
proteomics/NNS
deciphered/VBD
in/IN
panel/NN
A/NN
,/,
and/CC
rest/VBP
in/IN
panel/NN
B/NN
./.
====================
The/DT
results/NNS
of/IN
screening/VBG
putative/JJ
drug/NN
targets/NNS
in/IN
Bordetella/FW
petrii/NN
DSM/NN
12804/CD
deciphered/VBD
(/(
A/DT
)/)
,/,
where/WRB
numbers/NNS
in/IN
left/NN
hand/NN
side/JJ
indicates/VBZ
the/DT
identified/VBN
drug/NN
targets/NNS
after/IN
completion/NN
of/IN
each/DT
step/NN
./.
====================
(/(
B/NN
)/)
The/DT
resulted/VBD
drug/NN
targets/NNS
in/IN
each/DT
step/NN
represented/VBN
using/VBG
bar/JJ
chart/NN
./.
====================
DEG/NN
,/,
Database/NN
of/IN
Essential/JJ
Gene/NN
;/:
BLAST/NN
,/,
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
;/:
VFDB/NN
,/,
Virulence/NNP
Factor/NN
Database/NN
;/:
KEGG/NN
,/,
Kyoto/NN
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
./.
====================
The/DT
lipopolysaccharide/NN
biosynthesis/NN
pathway/NN
of/IN
Bordetella/FW
petrii/NN
explored/VBD
from/IN
Kyoto/NN
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
[/(
46/CD
]/)
web/NN
server/RB
./.
====================
The/DT
key/JJ
protein/NN
lpxD/NN
(/(
KEGG/NN
ID/NN
:/:
Bpet2525/NN
)/)
in/IN
the/DT
pathway/NN
highlighted/JJ
in/IN
red/JJ
color/NN
./.
====================
The/DT
protein-protein/JJ
network/NN
study/NN
of/IN
drug/NN
targets/NNS
namely/RB
,/,
lpxD/NN
,/,
and/CC
lpxC/NN
depicted/JJ
in/IN
section/NN
(/(
A/NN
)/)
and/CC
(/(
B/NN
)/)
respectively/RB
./.
====================
The/DT
conserved/VBN
amino/NN
acid/NN
residues/NNS
within/IN
left-handed/JJ
parallel/NN
beta/NN
helix/NN
(/(
LbH/JJ
)/)
domain/NN
of/IN
lpxD/NN
protein/NN
between/IN
Bordetella/FW
petrii/NN
and/CC
Pseudomonas/NN
aeruginosa/NN
(/(
PDB/NN
ID/NN
:/:
3PMO/CD
,/,
Chain/NNP
A/DT
)/)
are/VBP
identified/VBN
and/CC
deciphered/VBD
(/(
A/DT
)/)
./.
====================
The/DT
structural/JJ
super/NN
imposition/NN
between/IN
identified/VBN
drug/NN
target/NN
lpxD/NN
(/(
red/JJ
color/JJ
)/)
of/IN
B./FW
petrii/FW
and/CC
template/NN
(/(
PDB/NN
ID/NN
:/:
3pmo/CD
,/,
Chain/NNP
A/DT
)/)
(/(
blue/JJ
color/JJ
)/)
of/IN
P./FW
aeruginosa/NN
represented/VBN
(/(
B/NN
)/)
./.
====================
The/DT
backbone/NN
folding/VBG
pattern/NN
was/VBD
studied/VBN
through/IN
phi/NN
and/CC
psi/NN
torsion/NN
angle/JJ
in/IN
Ramachandran/NN
plot/NN
represented/VBN
(/(
C/NN
)/)
./.
====================
The/DT
overall/JJ
model/NN
quality/NN
evaluated/VBD
and/CC
deciphered/VBD
(/(
D/NN
)/)
,/,
where/WRB
the/DT
black/JJ
dot/RB
in/IN
the/DT
plot/NN
represents/VBZ
for/IN
predicted/VBN
structural/JJ
model/NN
of/IN
lpxD/NN
,/,
falls/VBZ
within/IN
the/DT
range/NN
of/IN
X-ray/NN
and/CC
NMR/NN
model/NN
quality/NN
./.
====================
The/DT
errors/NNS
within/IN
the/DT
non-bonded/JJ
interaction/NN
plotted/JJ
(/(
E/NN
)/)
,/,
the/DT
amino/NN
acid/NN
residues/NNS
and/CC
percentage/NN
of/IN
error/JJ
represented/VBN
in/IN
X-axis/NN
and/CC
Y-axis/NN
respectively/RB
,/,
the/DT
deep/JJ
black/JJ
color/JJ
represents/VBZ
error/NN
regions/NNS
in/IN
corresponding/VBG
amino/NN
acid/NN
residues/NNS
during/IN
non-bonded/JJ
interaction/NN
./.
====================
Chemical/JJ
structures/NNS
of/IN
nine/CD
natural/JJ
compounds/NNS
:/:
ajoene/DT
(/(
A/DT
)/)
,/,
allicin/NN
(/(
B/NN
)/)
,/,
cinnamaldehyde/JJ
(/(
C/NN
)/)
,/,
curcumin/NN
(/(
D/NN
)/)
,/,
gallotannin/NN
(/(
E/NN
)/)
,/,
isoorientin/NN
(/(
F/NN
)/)
,/,
isovitexin/NN
(/(
G/NN
)/)
,/,
neral/JJ
(/(
H/NN
)/)
,/,
and/CC
vitexin/FW
(/(
I/NN
)/)
./.
====================
Interaction/NN
profile/NN
of/IN
nine/CD
natural/JJ
compounds/NNS
:/:
ajoene/DT
(/(
A/DT
)/)
,/,
allicin/NN
(/(
B/NN
)/)
,/,
cinnamaldehyde/JJ
(/(
C/NN
)/)
,/,
curcumin/NN
(/(
D/NN
)/)
,/,
gallotanin/NN
(/(
E/NN
)/)
,/,
isoorientin/NN
(/(
F/NN
)/)
,/,
isovitexin/NN
(/(
G/NN
)/)
,/,
neral/JJ
(/(
H/NN
)/)
,/,
and/CC
vitexin/FW
(/(
I/NN
)/)
with/IN
proposed/JJ
drug/NN
target/NN
(/(
lpxD/NN
protein/NN
)/)
of/IN
Bordetella/FW
petrii/FW
./.
====================
Amino/DT
acid/NN
residues/NNS
participated/JJ
in/IN
hydrogen/NN
bonding/VBG
and/CC
interacting/VBG
within/IN
a/DT
distance/NN
of/IN
4Å/NN
in/IN
the/DT
active/JJ
pocket/NN
of/IN
LbH/JJ
domain/NN
of/IN
lpxD/NN
protein/NN
with/IN
natural/JJ
compounds/NNS
was/VBD
deciphered/VBN
here/RB
./.
====================
Twelve/CD
putative/JJ
and/CC
virulent/JJ
drug/NN
targets/NNS
associated/VBN
in/IN
three/CD
unique/JJ
pathways/NNS
of/IN
Bordetella/FW
petrii/NN
====================
Protein-protein/NN
interaction/NN
of/IN
selected/VBN
drug/NN
targets/NNS
of/IN
Bordetella/FW
petrii/NN
====================
Two/CD
proposed/JJ
drug/NN
targets/NNS
(/(
lpxD/NN
,/,
lpxC/NN
)/)
of/IN
Bordetella/FW
petrii/NN
along/IN
with/IN
their/PRP$
homologous/JJ
====================
Collected/JJ
information/NN
about/IN
selected/VBN
nine/CD
natural/JJ
compounds/NNS
against/IN
Bordetella/FW
petrii/NN
====================
Polar/JJ
contact/NN
information/NN
obtained/VBN
from/IN
docking/NN
calculation/NN
between/IN
selected/VBN
natural/JJ
compounds/NNS
and/CC
drug/NN
target/NN
(/(
lpxD/NN
)/)
of/IN
Bordetella/FW
petrii/NN
====================
Close/NN
amino/NN
acid/NN
residues/NNS
of/IN
drug/NN
target/NN
(/(
lpxD/NN
)/)
of/IN
Bordetella/FW
petrii/NN
participating/VBG
during/IN
interaction/NN
with/IN
nine/CD
natural/JJ
compounds/NNS
within/IN
a/DT
distance/NN
of/IN
4/CD
Å/CD
====================
